See more : Taeyang Metal Industrial Co., Ltd. (004100.KS) Income Statement Analysis – Financial Results
Complete financial analysis of Aclaris Therapeutics, Inc. (ACRS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aclaris Therapeutics, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Globalink Investment Inc. (GLLIR) Income Statement Analysis – Financial Results
- SNP Schneider-Neureither & Partner SE (SHF.DE) Income Statement Analysis – Financial Results
- Heilongjiang ZBD Pharmaceutical Co., Ltd. (603567.SS) Income Statement Analysis – Financial Results
- C.H. Robinson Worldwide Inc (CH1A.DE) Income Statement Analysis – Financial Results
- Shandong Bohui Paper Industry Co., Ltd. (600966.SS) Income Statement Analysis – Financial Results
Aclaris Therapeutics, Inc. (ACRS)
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 31.25M | 29.75M | 6.76M | 6.48M | 4.23M | 10.09M | 1.68M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 18.08M | 11.96M | 4.71M | 5.13M | 4.06M | 6.85M | 1.21M | 120.00K | 90.00K | 0.00 | 0.00 |
| Gross Profit | 13.17M | 17.79M | 2.05M | 1.35M | 172.00K | 3.24M | 476.00K | -120.00K | -90.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 42.14% | 59.80% | 30.29% | 20.81% | 4.07% | 32.12% | 28.28% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 98.38M | 77.81M | 43.81M | 31.73M | 64.90M | 63.01M | 39.79M | 33.48M | 15.34M | 6.51M | 3.49M |
| General & Administrative | 31.10M | 25.13M | 23.62M | 20.53M | 27.16M | 27.65M | 33.11M | 15.09M | 5.33M | 2.03M | 1.77M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 283.00K | 671.00K | 48.00M | 85.00K | 3.30M | 0.00 | 0.00 | 0.00 |
| SG&A | 31.10M | 25.13M | 23.62M | 20.53M | 27.83M | 75.65M | 33.11M | 15.09M | 5.33M | 2.03M | 1.77M |
| Other Expenses | 0.00 | 2.95M | -1.14M | -424.00K | -2.48M | 2.68M | 2.07M | 488.00K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 130.80M | 102.95M | 67.43M | 52.26M | 92.73M | 138.66M | 72.90M | 48.57M | 20.67M | 8.53M | 5.26M |
| Cost & Expenses | 128.61M | 114.91M | 72.15M | 57.39M | 96.78M | 145.51M | 74.11M | 48.57M | 20.67M | 8.53M | 5.26M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 104.00K | 16.00K | 21.00K |
| Interest Expense | 0.00 | 4.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 863.00K | 797.00K | 923.00K | 1.32M | 1.59M | 1.32M | 402.00K | 120.00K | 90.00K | 12.00K | 11.00K |
| EBITDA | -117.57M | -84.36M | -65.06M | -48.20M | -90.84M | -80.78M | -53.45M | -48.57M | -20.67M | -8.52M | -5.25M |
| EBITDA Ratio | -376.22% | -267.74% | -607.08% | -785.44% | -1,751.83% | -1,341.93% | -4,303.21% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -97.36M | -85.15M | -65.38M | -50.91M | -111.06M | -135.41M | -72.42M | -48.57M | -20.67M | -8.53M | -5.26M |
| Operating Income Ratio | -311.55% | -286.21% | -967.08% | -785.44% | -2,627.35% | -1,341.93% | -4,303.21% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 8.51M | 2.95M | -1.14M | -424.00K | -2.48M | 2.68M | -15.99M | 488.00K | 104.00K | 16.00K | 21.00K |
| Income Before Tax | -88.85M | -86.91M | -90.87M | -51.34M | -113.54M | -132.74M | -70.35M | -48.08M | -20.56M | -8.52M | -5.24M |
| Income Before Tax Ratio | -284.32% | -292.11% | -1,343.96% | -791.98% | -2,686.11% | -1,315.41% | -4,180.21% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -367.00K | 1.75M | 23.42M | -182.00K | 29.31M | 2.68M | -1.83M | -120.00K | -90.00K | 0.00 | 0.00 |
| Net Income | -88.48M | -88.66M | -114.28M | -51.15M | -142.85M | -132.74M | -68.52M | -48.08M | -20.56M | -8.52M | -5.24M |
| Net Income Ratio | -283.15% | -298.00% | -1,690.30% | -789.17% | -3,379.47% | -1,315.41% | -4,071.48% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.27 | -1.36 | -2.01 | -1.20 | -3.46 | -4.03 | -2.44 | -2.25 | -3.37 | -0.80 | -0.49 |
| EPS Diluted | -1.27 | -1.36 | -2.01 | -1.20 | -3.46 | -4.03 | -2.44 | -2.25 | -3.37 | -0.80 | -0.49 |
| Weighted Avg Shares Out | 69.81M | 65.21M | 56.73M | 42.54M | 41.32M | 32.91M | 28.10M | 21.42M | 6.11M | 10.66M | 10.66M |
| Weighted Avg Shares Out (Dil) | 69.81M | 65.21M | 56.73M | 42.54M | 41.32M | 32.91M | 28.10M | 21.42M | 6.11M | 10.66M | 10.66M |
Has Aclaris Therapeutics (ACRS) Outpaced Other Medical Stocks This Year?
Aclaris Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Misses Revenue Estimates
Aclaris Therapeutics to Participate in the SVB Leerink Virtual 11th Annual Global Healthcare Conference
Aclaris Therapeutics to Participate in the H.C. Wainwright BioConnect Virtual Conference
Aclaris Therapeutics to Participate in Upcoming Investor Conferences
Aclaris Therapeutics (ACRS) Reports Q3 Loss, Lags Revenue Estimates
Aclaris Therapeutics Announces Proposed Settlement and Settlement Hearing of Stockholder Derivative Action
Aclaris Therapeutics Reports Second Quarter 2021 Financial Results and Provides a Corporate Update
Aclaris Therapeutics (ACRS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Source: https://incomestatements.info
Category: Stock Reports